This is a routine Nasdaq compliance reverse split with no fundamental business change. Monitor for potential Nasdaq delisting risk if the post-split share price fails to maintain the $1.00 minimum bid price. The warrant adjustment is purely mechanical and does not change the economics for warrant holders.
Price Chart
Executive Summary
Silexion Therapeutics Corp effected a 1-for-10 reverse share split of its ordinary shares, effective May 28, 2026, to maintain Nasdaq minimum bid price compliance. The authorized share capital remains $796,500, now consisting of 5,900,000 ordinary shares with par value increased from $0.0135 to $0.135 per share. Outstanding warrants were proportionally adjusted: each warrant now exercisable for 1/10th of an ordinary share at an increased exercise price of $15,525.00 per share.
Key Facts
- 1-for-10 reverse share split effective after close of trading on May 28, 2026
- Authorized share capital unchanged at $796,500, now 5,900,000 ordinary shares
- Par value increased from $0.0135 to $0.135 per share
- Warrant exercise price adjusted from $1,552.50 to $15,525.00 per share
- Each warrant now exercisable for 1/10th of an ordinary share
- Reverse split approved by shareholders at extraordinary general meeting on May 5, 2026
- Trading symbols SLXN (ordinary shares) and SLXNW (warrants) unchanged
- CUSIP for ordinary shares changed to G1281K148; warrant CUSIP remains G1281K114
Financial Impact
No new capital raised or deployed. Reverse split is a mechanical share consolidation with no change to aggregate authorized capital ($796,500). Warrant adjustment is a proportional anti-dilution adjustment.
Risk Factors
- Post-split share price may still fail to maintain Nasdaq minimum bid price requirement
- Reduced share count and higher absolute share price may reduce liquidity for retail traders
- Warrant exercise price of $15,525.00 per share makes warrants deeply out-of-the-money and likely worthless
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-002988 |
| Exhibit: exhibit_4-1.htm | 0001178913-26-002988 |
| Exhibit: exhibit_3-1.htm | 0001178913-26-002988 |
| Document: 0001178913-26-002988-index-headers.html | 0001178913-26-002988 |
| Document: 0001178913-26-002988-index.html | 0001178913-26-002988 |
| Document: 0001178913-26-002988.txt | 0001178913-26-002988 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 21w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
May 26, 2026 22w ago | 8-K | $0.0334 $0.0184 | ▼ −44.91% | ▼ −47.63% | — |
May 18, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▼ −61.08% | ▼ −65.93% | — |
May 15, 2026 23w ago | 8-K | $0.0334 $0.0130 | ▲ +61.08% | ▲ +65.93% | — |
May 13, 2026 23w ago | 8-K | $0.0334 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers